Market Exclusive

ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Submission of Matters to a Vote of Security Holders

ARDELYX, INC. (NASDAQ:ARDX) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07Submission of Matters to a Vote Security Holders.

On June13, 2018, Ardelyx, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) at the Company’s principal executive offices located at 34175 Ardenwood Blvd., Suite 200 (2nd Floor), Fremont, California 94555. Only stockholders of record at the close of business on April20, 2018, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 47,603,568 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 43,952,888shares of the Company’s common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April26, 2018.

Proposal No.1 – Election of Directors

The Company’s stockholders elected the ClassI director nominees below to the Company’s Board of Directors (the “Board”) to hold office until the 2021 Annual Meeting of Stockholders or until their successors are elected.

Class I Director Nominees

VotesFor

VotesWithheld

BrokerNon‑Votes

William Bertrand, Jr., Esq.

32,172,136

4,814,123

6,966,629

Annalisa Jenkins, MBBS, FRCP

25,515,353

11,470,906

6,966,629

Jan Lundberg, Ph.D.

35,698,931

1,287,328

6,966,629

Proposal No.2 – Ratification of Selection of Independent Registered Accounting Firm

The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of Ernst& Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December31, 2018.

Votes For

VotesAgainst

Abstentions

BrokerNon-Votes

43,821,510

96,384

34,994

0

About ARDELYX, INC. (NASDAQ:ARDX)
Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia. RDX022 is its oral, non-absorbed potassium-binder. Its development programs also include RDX009 Program, RDX013 Program and RDX011 Program.

Exit mobile version